PMID- 26168493
OWN - NLM
STAT- MEDLINE
DCOM- 20151001
LR  - 20150714
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 35
IP  - 8
DP  - 2015 Aug
TI  - Immunopotentiator from Pantoea agglomerans Prevents Atopic Dermatitis Induced by 
      Dermatophagoides farinae Extract in NC/Nga Mouse.
PG  - 4501-8
AB  - BACKGROUND/AIM: Pantoea agglomerans LPS (immunopotentiator from Pantoea 
      agglomerans 1: IP-PA1) has been reported to have anti-inflammatory effects in in 
      vitro and in vivo models. The aim of the present study was to investigate the 
      effects of orally-administered IP-PA1 on atopic dermatitis (AD) symptoms induced 
      by Dermatophagoides farinae body extract (DFE) in NC/Nga mice. MATERIALS AND 
      METHODS: Using the NC/Nga AD murine model, mice were orally administered 0.1% 
      (High) or 0.01% (Low) water-containing IP-PA1. Skin lesion assessment and blood 
      collection from the caudal vein was performed on days 0, 7, 21 and 31. On day 31, 
      all mice were sacrificed and blood, skin, spleen, as well as intestine samples, 
      were obtained. RESULTS: Assessment score of the skin lesion and serum 
      immunoglobulin E (IgE) level of both IP-PA1 groups were significantly lower than 
      that of the DFE group on days 14 and 21. The serum periostin and thymus and 
      activation-regulated chemokine (TARC) level of IP-PA1-Low group was significantly 
      lower than that of the DFE group on day 31. On histological examination of the 
      skin, hyperplasia of epidermal and dermal layers and infiltration of inflammatory 
      cells were suppressed by IP-PA1 administration. Deposition of periostin was 
      observed in the DFE group skin tissue. Moreover, the CD4(+)/CD8(+) ratio of 
      splenic T-cells increased by IP-PA1 administration. CONCLUSION: IP-PA1 
      administration may have an inhibitory effect on AD skin lesions.
CI  - Copyright(c) 2015 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Wakame, Koji
AU  - Wakame K
AD  - Department of Pharmacology, Hokkaido Pharmaceutical University School of 
      Pharamacy, Sapporo, Hokkaido, Japan wakame-k@hokuyakudai.ac.jp.
FAU - Komatsu, Ken-Ichi
AU  - Komatsu K
AD  - Department of Pharmacology, Hokkaido Pharmaceutical University School of 
      Pharamacy, Sapporo, Hokkaido, Japan.
FAU - Inagawa, Hiroyuki
AU  - Inagawa H
AD  - Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan Control 
      of Innate Immunity, Technology Research Association, Takamatsu-shi, Kagawa, Japan 
      Macrophi Inc., Takamatsu-shi, Kagawa, Japan.
FAU - Nishizawa, Takashi
AU  - Nishizawa T
AD  - Macrophi Inc., Takamatsu-shi, Kagawa, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Ccl17 protein, mouse)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Chemokine CCL17)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Postn protein, mouse)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adjuvants, Immunologic/*therapeutic use
MH  - Animals
MH  - CD4-CD8 Ratio
MH  - Cell Adhesion Molecules/blood
MH  - Chemokine CCL17/blood
MH  - Dermatitis, Atopic/immunology/*prevention & control
MH  - Dermatophagoides farinae/immunology
MH  - Disease Models, Animal
MH  - Immunoglobulin E/blood/immunology
MH  - Lipopolysaccharides/administration & dosage/*pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Pantoea/*immunology/metabolism
MH  - Skin/immunology
MH  - T-Lymphocytes/immunology
OTO - NOTNLM
OT  - NC/Nga mice
OT  - Pantoea agglomerans
OT  - atopic dermatitis
OT  - dermatophagoides farinae body extract
OT  - lipopolysaccharide
EDAT- 2015/07/15 06:00
MHDA- 2015/10/02 06:00
CRDT- 2015/07/14 06:00
PHST- 2015/07/14 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2015/10/02 06:00 [medline]
AID - 35/8/4501 [pii]
PST - ppublish
SO  - Anticancer Res. 2015 Aug;35(8):4501-8.